Tacrolimus is a drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants.
An interesting new study describes the emergence of several such variants from a chronically immunosuppressed COVID-19 patient, who remained infected for over 170 days before clearing the virus.
A new study shows that rapamycin, an immunosuppressive drug used in some cancers, and its analogs, may have an undesirable effect on viral entry into the host cells. This finding could inform their use to treat symptomatic COVID-19.
A new research paper posted to the medRxiv* preprint server describes the changes in genomic sequence observed during the course of infection in a patient on the drug tacrolimus, along with steroids, both potent immunosuppressants, and who also received convalescent plasma treatment. These mutations were observed to occur within three weeks from infection.
Researchers in Switzerland and Germany have identified host cell factors required for coronavirus replication that could serve as targets for treatment with clinically-approved drugs.
Long-term use of a medication used to treat kidney transplant patients may not be necessary in individuals with low-to-moderate risk of organ rejection, according to the results of a study led by a University of Cincinnati transplant researcher.
Duke-NUS Medical School researchers, together with collaborators in Singapore, have designed armored immune cells that can attack recurring cancer in liver transplant patients, while temporarily evading immunosuppressant drugs patients take to avoid organ rejection.
People taking immunosuppressive drugs to prevent organ transplant rejection or to treat inflammatory or autoimmune diseases do not fare worse than others on average when they are hospitalized with COVID-19, according to a study from researchers at the Johns Hopkins Bloomberg School of Public Health.
The Covid-19 pandemic shows the importance of medical research in the treatment of lung diseases. The Medical University of Vienna is renowned the world over in the field of lung transplantation medicine.
Immune inflammatory mediators are critical in pathology, transplantation, and regenerative medicine, scientists report in The American Journal of Pathology
The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented online during ASN Kidney Week 2020 Reimagined October 19-October 25.
Amid the coronavirus disease (COVID-19) pandemic, many theories have emerged about the disease and the treatments that can in supportive care. A recent theory emerged that suggests non-steroidal anti-inflammatory drugs (NSAIDs) might exacerbate the symptoms of the novel coronavirus. Now, a new study shows that there is no evidence for or against the use of NSAIDS, particularly ibuprofen, for patients with COVID-19.
A recent study has found that there is no evidence for or against the use of non-steroidal anti-inflammatory drugs such as ibuprofen for patients with COVID-19.
A new practice guideline published in the journal CMAJ in February 2020 describes five types of drug interactions possible with the use of cannabis. Cannabis is a plant-derived drug containing the psychoactive ingredient delta-9-tetrahydrocannabinol (THC) and non-psychoactive cannabidiol (CBD). These cannabinoids are broken down by the liver enzymes cytochrome P450 C(YP)34A, and CYP2CC9.
More than ever before, Alzheimer's researchers understand that a variety of approaches will be needed - most likely used in combination - for effective treatment of the disease.
University of Maryland School of Medicine researchers found that lung transplant recipients who had early signs of organ rejection could increase their chances of survival by using an inhaled form of the immunosuppression drug cyclosporine.
Lung transplantation can prolong the lives of patients with end-stage lung disease, but the median survival rate after lung transplant is less than six years, which has improved only slightly in recent decades.
Preliminary results from a $5.2 million clinical trial led by University of Cincinnati researchers show that the immunosuppressive drug belatacept can help safely and effectively treat kidney transplant patients without the negative long-term side effects of traditional immunosuppressive regimens, the study's leaders announced this week.
According to the Deutsche Multiple Sklerose Gesellschaft, around 200,000 people in Germany suffer from multiple sclerosis- a serious neurological condition that has no known cure.
Human pluripotent stem cells can infinitely self-renew and develop into all major cell types in the body, making them important for organ repair and replacement. But culturing them in large quantities can be expensive. Now, scientists at Japan's Kyoto University, with colleagues in India and Iran, have developed a more cost-effective culture by using a new combination of chemical compounds.
Development of de novo donor-specific antibodies (dnDSA) is known to cause graft failure. Therefore, a protocol aimed at prospective monitoring and treating dnDSA--before it can cause graft damage--was developed for kidney transplant recipients at Children National Health System.